MX2013002390A - Tratamiento de infarto de miocardio usando antagonistas de tgf-beta. - Google Patents

Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.

Info

Publication number
MX2013002390A
MX2013002390A MX2013002390A MX2013002390A MX2013002390A MX 2013002390 A MX2013002390 A MX 2013002390A MX 2013002390 A MX2013002390 A MX 2013002390A MX 2013002390 A MX2013002390 A MX 2013002390A MX 2013002390 A MX2013002390 A MX 2013002390A
Authority
MX
Mexico
Prior art keywords
myocardial infarction
tgf
treatment
beta antagonists
patient
Prior art date
Application number
MX2013002390A
Other languages
English (en)
Other versions
MX354535B (es
Inventor
Geoffrey Y Akita
Scott Lonning
Richard C Gregory Jr
Amelia B Kudej
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2013002390A publication Critical patent/MX2013002390A/es
Publication of MX354535B publication Critical patent/MX354535B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)

Abstract

En la presente se describe un método de tratamiento a un paciente que sufra un infarto de miocardio, particularmente un infarto de miocardio agudo, o para disminuir una consecuencia adversa de un infarto de miocardio en un paciente, que consiste en administrar al paciente un antagonista de TGF-ß durante la etapa aguda del infarto de miocardio.
MX2013002390A 2010-09-01 2011-09-01 TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. MX354535B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37931510P 2010-09-01 2010-09-01
PCT/US2011/001536 WO2012030394A1 (en) 2010-09-01 2011-09-01 Treatment of myocardial infarction using tgf - beta antagonists

Publications (2)

Publication Number Publication Date
MX2013002390A true MX2013002390A (es) 2013-08-27
MX354535B MX354535B (es) 2018-03-09

Family

ID=44654454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002390A MX354535B (es) 2010-09-01 2011-09-01 TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.

Country Status (18)

Country Link
US (2) US20130330352A1 (es)
EP (1) EP2611831B1 (es)
JP (2) JP6377348B2 (es)
KR (1) KR101939965B1 (es)
CN (1) CN103201292B (es)
BR (1) BR112013004850B1 (es)
CA (1) CA2809568C (es)
CL (1) CL2013000586A1 (es)
ES (1) ES2715177T3 (es)
IL (1) IL225018A (es)
MX (1) MX354535B (es)
MY (1) MY165160A (es)
NZ (2) NZ624382A (es)
PL (1) PL2611831T3 (es)
RU (1) RU2637088C2 (es)
SG (2) SG187953A1 (es)
TR (1) TR201903101T4 (es)
WO (1) WO2012030394A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096458A1 (en) * 2009-02-18 2010-08-26 Cormatrix Cardiovascular, Inc. Compositions and methods for preventing cardiac arrhythmia
KR102258457B1 (ko) * 2013-03-11 2021-05-31 젠자임 코포레이션 조작된 항-tgf-베타 항체 및 항원-결합 단편
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
HUE061424T2 (hu) * 2015-10-30 2023-06-28 Univ California Növekedési faktor bétára reagáló polipeptidek transzformálása és azok felhasználási módszerei
WO2017123550A1 (en) * 2016-01-11 2017-07-20 Autotelic Llc Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
US20170218040A1 (en) * 2016-02-02 2017-08-03 Julio A. Camarero Palao Proteolically resistant cyclotides with angiotensin 1-7 like activity
AU2017310344A1 (en) * 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
KR102635723B1 (ko) 2017-05-04 2024-02-08 악셀레론 파마 인코포레이티드 Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
WO2023054712A1 (ja) 2021-09-30 2023-04-06 ペプチドリーム株式会社 ペプチド

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP2154535A1 (en) 1998-12-10 2010-02-17 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7763580B2 (en) * 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP1848424B1 (en) 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
CN104151427B (zh) * 2005-02-08 2017-09-08 根茨美公司 针对TGFβ的抗体
KR20110114684A (ko) * 2009-01-26 2011-10-19 인터뮨, 인크. 급성 심근 경색 및 연관된 질환을 치료하는 방법
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido

Also Published As

Publication number Publication date
CN103201292A (zh) 2013-07-10
CN103201292B (zh) 2016-09-14
IL225018A (en) 2017-11-30
RU2013114365A (ru) 2014-10-10
EP2611831B1 (en) 2018-12-12
EP2611831A1 (en) 2013-07-10
CA2809568A1 (en) 2012-03-08
SG187953A1 (en) 2013-03-28
AU2011296574A1 (en) 2013-03-21
KR20130111550A (ko) 2013-10-10
US10633437B2 (en) 2020-04-28
NZ608813A (en) 2014-11-28
TR201903101T4 (tr) 2019-03-21
SG10201506909PA (en) 2015-10-29
AU2011296574B2 (en) 2015-12-03
MY165160A (en) 2018-02-28
NZ624382A (en) 2015-05-29
KR101939965B1 (ko) 2019-01-18
BR112013004850B1 (pt) 2020-04-07
WO2012030394A1 (en) 2012-03-08
MX354535B (es) 2018-03-09
US20170233465A1 (en) 2017-08-17
JP6377348B2 (ja) 2018-08-22
CL2013000586A1 (es) 2013-08-30
JP2017193543A (ja) 2017-10-26
BR112013004850A2 (pt) 2016-05-31
US20130330352A1 (en) 2013-12-12
RU2637088C2 (ru) 2017-11-29
JP2013542179A (ja) 2013-11-21
PL2611831T3 (pl) 2019-05-31
ES2715177T3 (es) 2019-06-03
CA2809568C (en) 2019-06-11

Similar Documents

Publication Publication Date Title
MX2013002390A (es) Tratamiento de infarto de miocardio usando antagonistas de tgf-beta.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
MX2011007930A (es) Conjugados de insulina cristalina.
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
MX348941B (es) Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo.
MY150600A (en) Use of opioid antagonists for treating urinary retention
PH12015501088A1 (en) Dimeric compounds
WO2012158672A3 (en) Compounds for use in treatment of mucositis
PH12014500990A1 (en) Methods for treating gout flares
SG10201804034QA (en) Methods for treating hypotension
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
TR201900438T4 (tr) Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
GB201022049D0 (en) Methods
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
EA201071350A1 (ru) Композиции и способы для лечения воспаления роговицы
MX362111B (es) Un metodo para mejorar la funcion hepatica.
MX351765B (es) Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UA60249U (ru) Способ лечения острого инфаркта миокарда
UA106224C2 (en) Crystalline insulin-conjugates

Legal Events

Date Code Title Description
FG Grant or registration